Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers

Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers

Abstract Introduction People with type 2 diabetes have increased risk of dementia. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidenc...

Full description

Bibliographic Details
Main Authors: Caroline Holm Nørgaard, Sarah Friedrich, Charlotte Thim Hansen, Thomas Gerds, Clive Ballard, Daniel Vega Møller, Lotte Bjerre Knudsen, Kajsa Kvist, Bernard Zinman, Ellen Holm, Christian Torp‐Pedersen, Lina Steinrud Mørch
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
dementia
glucagon‐like peptide‐1 receptor agonists
randomized controlled trial
real‐world evidence
type 2 diabetes
Online Access:https://doi.org/10.1002/trc2.12268

Internet

https://doi.org/10.1002/trc2.12268

Similar Items